MITF and melanoma: In addition, since BRAF suppresses mitochondrial function via the downregulation of MITF, melanoma cells treated by BRAF-targeted drugs restore oxidative phosphorylation to maintain their survival, leading to adaptive resistance to targeted therapy (51).